仁和药业：公司2021年获得恩替卡韦片药品注册证书

Core Viewpoint - Renhe Pharmaceutical (000650) has received the registration certificate for Entecavir tablets in 2021, which is an oral antiviral drug used for the treatment of hepatitis B infection [1] Company Summary - The company specializes in Entecavir, which selectively inhibits the hepatitis B virus [1] - Entecavir is primarily used for treating adults with active viral replication and persistently elevated serum transaminases, or with histologically active lesions in chronic hepatitis B [1]